| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 05/08/2002 | CN1348460A Acetal Benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 05/08/2002 | CN1348454A Tetracyclic azepinoindole compounds as 5-HT receptor ligands |
| 05/08/2002 | CN1348453A Derivatives of pyrimido [6.1-a] isoquinolin-4-one |
| 05/08/2002 | CN1348452A Derivatives of pyrimido [6,1-a] isoquinolin -4-one |
| 05/08/2002 | CN1348447A 4,5-diaryl-3(i(2H))-furanone derivatives as cyclooxygenase-2 inhibitors |
| 05/08/2002 | CN1348444A 丝氨酸蛋白酶抑制剂 Serine protease inhibitors |
| 05/08/2002 | CN1348443A N-substituted-N'-substituted urea derivative and medicinal compositions containing the same |
| 05/08/2002 | CN1348439A New compounds, their preparation and use |
| 05/08/2002 | CN1348375A Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation |
| 05/08/2002 | CN1348374A Combined preparation of anti-infectiously active compounds which inhibit the 2-c-methylerythrose-4-metabolic pathway, and inhibitors of lipid metabolism |
| 05/08/2002 | CN1348372A 药物用途 Drug use |
| 05/08/2002 | CN1348370A Cyclic protein tyrosine kinase inhibitors |
| 05/08/2002 | CN1347881A 法呢基蛋白转移酶抑制剂 Farnesyl protein transferase inhibitor |
| 05/08/2002 | CN1347874A Application of small dosage of aminoguanidine in anti-senility and preventing and treating senile diseases |
| 05/08/2002 | CN1084208C Medicine for treating Baisai's disease and its preparing method |
| 05/07/2002 | US6384261 Treating endothelin-mediated disorders; inhibitory binding of endothilin peptides to eta and/or etb receptors; elucidating the physiological and pathophysiological roles and isolating endothelin receptors; antagonists |
| 05/07/2002 | US6384259 Heat resistant, sterile dosage suitable for reconstitution with a vehicle into an injectible, particle-free product for parenteral administration |
| 05/07/2002 | US6384236 N-(aroyl)glycine hydroxamic acid derivatives and related compounds |
| 05/07/2002 | US6384222 N-benzenesulfonyl-L-proline compounds, preparation method and method for using the compounds in therapy |
| 05/07/2002 | US6384220 Antidiabetic agents increasing the expression of glucokinase (gk) to improve glucose tolerance; increase in glucose exposure coupled through gk in beta-cells to increase insulin secretion and in hepatocytes to increase glycogen deposition |
| 05/07/2002 | US6384191 Receptors for fibroblast growth factors |
| 05/07/2002 | US6384189 Compositions for stimulating TGF-β activity |
| 05/07/2002 | US6384084 Histochrome and its therapeutic use in ophthalmology |
| 05/07/2002 | US6384080 Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase |
| 05/07/2002 | US6384077 Highly purified EPA for treatment of schizophrenia and related disorders |
| 05/07/2002 | US6384076 Inhibition or erythrocyte sickling by N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester |
| 05/07/2002 | US6384074 Activating cell growth in human by applying specified plant extract to skin |
| 05/07/2002 | US6384072 Carbamyl substituted compounds with ether groups |
| 05/07/2002 | US6384070 Restenosis, kidney diseases, lung diseases |
| 05/07/2002 | US6384062 Pharmaceutical composition |
| 05/07/2002 | US6384056 Cognition activators and nerve and vision disorders |
| 05/07/2002 | US6384047 Breathing disorders and hypotensive agents |
| 05/07/2002 | US6384046 Treating neointimal proliferation and thickening |
| 05/07/2002 | US6384042 Systemic use of 5-HT3 receptor antagonists against rheumatic inflammatory processes |
| 05/07/2002 | US6384041 Bicyclic sPLA2 inhibitors |
| 05/07/2002 | US6384039 QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death |
| 05/07/2002 | US6384036 Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors |
| 05/07/2002 | US6384035 Heterocycles useful in the treatment of benign prostatic hyperplasia |
| 05/07/2002 | US6384028 Treatment of cardiovascular disorders, anticoagulants and valve replacement |
| 05/07/2002 | US6384027 Phthalocyanine analogs |
| 05/07/2002 | US6384024 Bile salt conjugates |
| 05/07/2002 | US6384022 Enzyme inhibitors |
| 05/07/2002 | US6384012 Use of isolated domains of type IV collagen to modify cell and tissue interactions |
| 05/07/2002 | US6383808 Antisense inhibition of clusterin expression |
| 05/07/2002 | US6383793 Human osteoclast-derived cathepsin |
| 05/07/2002 | US6383790 Pyrazolo(3,4-d)pyrimidine based compound; anticarcinogenic agents; antitumor agents |
| 05/07/2002 | US6383768 Method for producing in vitro the RNA-dependent RNA polymerase and terminal nucleotidyl transferase activities encoded by hepatitis C virus (HCV) |
| 05/07/2002 | US6383760 Contacting receptor with test compound, then determining if compound binds to receptor |
| 05/07/2002 | US6383522 Toxicity reduced composition containing an anti-neoplastic agent and a shark cartilage extract |
| 05/07/2002 | US6383521 Sponge extract (wondonin a) with antiangiogenesis and anticarcinogenic properties; non-cytotoxic |
| 05/07/2002 | US6383514 Hypocholesterolemic composition comprising a phytostanol ester and a tocopherol |
| 05/07/2002 | US6383510 Suppository form comprising an acid-labile active compound |
| 05/07/2002 | US6383500 Particles comprising amphiphilic copolymers, having a crosslinked shell domain and an interior core domain, useful for pharmaceutical and other applications |
| 05/07/2002 | US6383484 Antibodies to truncated VEGF-D and thereof |
| 05/07/2002 | CA2216535C Protein kinase c inhibitors |
| 05/07/2002 | CA2214884C Poly(hydroxy acid)/polymer conjugates for skin applications |
| 05/07/2002 | CA2145000C Compounds which are selective antagonists of the human nk3 receptor and their use as medicinal products and diagnostic tools |
| 05/07/2002 | CA2088760C Use of 2-phenyl-1,2-benzisoselanazol-3-(2h)-one |
| 05/02/2002 | WO2002034940A2 Methods for screening compounds that modulate lipid metabolism |
| 05/02/2002 | WO2002034922A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 05/02/2002 | WO2002034914A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 05/02/2002 | WO2002034913A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 05/02/2002 | WO2002034899A2 Tec kinase assay |
| 05/02/2002 | WO2002034895A2 Novel aggrecanase molecules |
| 05/02/2002 | WO2002034885A1 Sericin-containing material, process for producing the same and method of using the same |
| 05/02/2002 | WO2002034767A1 Vegf peptides and their use for inhibiting angiogenesis |
| 05/02/2002 | WO2002034753A2 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | WO2002034747A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
| 05/02/2002 | WO2002034741A2 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
| 05/02/2002 | WO2002034726A2 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | WO2002034721A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/02/2002 | WO2002034718A1 Amide derivatives as nmda receptor antagonists |
| 05/02/2002 | WO2002034716A2 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/02/2002 | WO2002034303A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | WO2002034293A2 Use of citric acid as antimicrobial agent or enhancer or as anticancer agent |
| 05/02/2002 | WO2002034289A1 Modulating angiogenesis |
| 05/02/2002 | WO2002034286A1 Methods for treating endocrine disorders |
| 05/02/2002 | WO2002034284A2 Methods of therapy for hiv infection |
| 05/02/2002 | WO2002034273A1 Compositions and methods for diagnosis and treatment of cardiovascular disorders |
| 05/02/2002 | WO2002034272A2 Methods of improving central nervous system functioning |
| 05/02/2002 | WO2002034263A1 Preventives/remedies for portal hypertension |
| 05/02/2002 | WO2002034262A1 Combination of catechin and quercetin for pharmaceutical or dietary use |
| 05/02/2002 | WO2002034260A1 6-methoxy-2-naphthylacetic acid prodrugs |
| 05/02/2002 | WO2002034259A1 Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction |
| 05/02/2002 | WO2002034257A1 Agents for recoverying from or preventing fatigue in the central nerve system and foods for recoverying from or preventing fatigue |
| 05/02/2002 | WO2002034253A1 Hair growth stimulant |
| 05/02/2002 | WO2002034247A2 Anticancer agents based on regulation of protein prenylation |
| 05/02/2002 | WO2002034243A2 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | WO2002034242A2 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | WO2002034241A2 Compounds comprising a phytosterol and/or phytostanol moiety and ascorbis acid and use thereof as weight regulating agents |
| 05/02/2002 | WO2002034233A2 Use of an association of a carotenoid and of an isoflavonoid for treating cutaneous symptoms of ageing |
| 05/02/2002 | WO2002034232A2 Use of carotenoids for treating ageing symptoms |
| 05/02/2002 | WO2002034231A2 Use of the association of at least an plant extract of genus rosmarinus and of at least a carotenoid |
| 05/02/2002 | WO2002034221A1 Dental care compositions |
| 05/02/2002 | WO2002034204A2 Calcilytic compounds |
| 05/02/2002 | WO2002034202A2 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
| 05/02/2002 | WO2002012537A3 Mutant trichosanthin |
| 05/02/2002 | WO2002011710A3 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 05/02/2002 | WO2002011677A3 Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| 05/02/2002 | WO2002005822A3 Compositions containing therapeutically active components having enhanced solubility |